Human retina and eye vascular tissue have angiogenic activity, which is closely related to vascular endothelial growth factor (VEGF).VEGF165 overexpression leads to pathological ocular angiogenesis, which is one of the main pathological causes of degenerative macular disease, diabetic macular edema, and diabetic retinopathy.

At present, anti-VEGF therapy is widely used to treat age-related macular degeneration (nAMD) and other vascular proliferative diseases. Patients normally need multiple injections every year.

The development strategy of NFS-10 is to use the optimized AAV vector to deliver therapeutic genes, endogenous long-acting expression of anti-VEGF antibodies, maintain a balanced plasma concentration, inhibit the growth of neovascularization, reduce vascular leakage, repair the damage of retinal capillary wall, slow down the progression of the disease and prevent visual loss. With this candidate drug, Neurophth is expecting to change multiple injections to single injection, to reduce patient suffering, enhance clinical safety, and improve compliance with clinical medication, thereby improving efficacy.